Adalimumab - část 3 - Adalimumab pro nové pacienty
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 981/2021-SML | 03. 08. 2021 | Fresenius Kabi s.r.o. | 915 200,00 | 832 000,00 | 915 200,00 | 832 000,00 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva Adalimumab část 3 signed 11082021.pdf | Písemná zpráva zadavatele | 11. 08. 2021 15:09 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Alliance Healthcare s. r. o. | Praha | |||||
| Fresenius Kabi s.r.o. | Praha 4 | |||||
| PHOENIX lékárenský velkoobchod, s.r.o. | Praha | |||||
| Amgen s.r.o. | Praha | |||||
| Avenier a.s. | Brno |
Price Actually Paid in Each Year of Performance
| 981/2021-SML | 2023 | 0,00 | 0,00 |
| 981/2021-SML | 2022 | 960 960,00 | 873 600,00 |
| 981/2021-SML | 2021 | 148 720,00 | 135 200,00 |